October 19, 2010 / 10:52 PM / 8 years ago

UPDATE 1-Boehringer wins first US OK in blood-thinner race

* One of at least 8 warfarin replacements being tested

* Market seen being worth more than $10 billion a year

LOS ANGELES, Oct 19 (Reuters) - German drugmaker Boehringer Ingelheim won the first U.S. approval for a new stroke-fighting medicine that will compete in an estimated $10 billion market for drugs to replace the 65-year-old blood thinner warfarin.

The Food and Drug Administration cleared Boehringer’s drug, Pradaxa, for preventing strokes in patients with a type of irregular heart beat.

The approval gives Boehringer a head start over several other drugmakers, including partners Bayer (BAYGn.DE) and Johnson & Johnson (JNJ.N), and Bristol-Myers Squibb Co (BMY.N) and Pfizer (PFE.N), that are working on competing drugs.

Pradaxa and potential rivals are alternatives to warfarin, a problematic medicine originally developed as rat poison.

Warfarin is the treatment of choice for people at high risk of stroke due to atrial fibrillation, a common form of irregular heart beat. But the drug interacts badly with food and other medicines, carries a high risk of bleeding and requires regular blood tests.

In September, an FDA advisory panel voted 9-0 to recommend approval of Pradaxa, which also carries a risk of serious bleeding.

The warfarin replacement market is expected to be worth more than $10 billion a year and possibly as much as $20 billion. Bayer Chief Executive Werner Wenning recently put the opportunity at $12 billion to $15 billion. [ID:nLDE68E078]

At least eight potential warfarin replacements are currently being tested by major drugmakers. [ID:nLDE67M0DP]

An estimated 2.3 million Americans have atrial fibrillation, and the prevalence is expected to grow to 5.6 million by 2050 as the population ages, Boehringer said.

Boehringer, now controlled by great-grandchildren of the company’s founder, suffered a setback in June when U.S. advisers rejected the company’s experimental sex pill for women. The company recently halted development of that drug. (Reporting by Lisa Richwine and Deena Beasley; Editing by Steve Orlofsky)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below